An Antibody Microarray Analysis of Serum Cytokines in Neurodegenerative Parkinsonian Syndromes

Overview

Journal Proteome Sci

Publisher Biomed Central

Date 2012 Nov 24

PMID 23173604

Citations 10

Authors

Philipp Mahlknecht

Sylvia Stemberger

Fabienne Sprenger

Johannes Rainer

Eva Hametner

Rudolf Kirchmair

Christoph Grabmer

Christoph Scherfler

Gregor K Wenning

Klaus Seppi

Werner Poewe

Markus Reindl

Affiliations

Soon will be listed here.

Abstract

Unlabelled:

Background: Microarray technology may offer a new opportunity to gain insight into disease-specific global protein expression profiles. The present study was performed to apply a serum antibody microarray to screen for differentially regulated cytokines in Parkinson's disease (PD), multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS).

Results: Serum samples were obtained from patients with clinical diagnoses of PD (n = 117), MSA (n = 31) and PSP/CBS (n = 38) and 99 controls. Cytokine profiles of sera from patients and controls were analyzed with a semiquantitative human antibody array for 174 cytokines and the expression of 12 cytokines was found to be significantly altered. In a next step, results from the microarray experiment were individually validated by different immunoassays. Immunoassay validation confirmed a significant increase of median PDGF-BB levels in patients with PSP/CBS, MSA and PD and a decrease of median prolactin levels in PD. However, neither PDGF-BB nor prolactin were specific biomarkers to discriminate PSP/CBS, MSA, PD and controls.

Conclusions: In our unbiased cytokine array based screening approach and validation by a different immunoassay only two of 174 cytokines were significantly altered between patients and controls.

Citing Articles

Blood inflammation relates to neuroinflammation and survival in frontotemporal lobar degeneration.

Malpetti M, Swann P, Tsvetanov K, Chouliaras L, Strauss A, Chikaura T Brain. 2024; 148(2):493-505.

PMID: 39155063 PMC: 7617268. DOI: 10.1093/brain/awae269.

Blood Biomarkers in Patients with Parkinson's Disease: A Review in Context of Anesthetic Care.

Joo J, Jeong J, Park H Diagnostics (Basel). 2023; 13(4).

PMID: 36832181 PMC: 9955162. DOI: 10.3390/diagnostics13040693.

Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson's Disease.

Zimmermann M, Brockmann K J Parkinsons Dis. 2022; 12(s1):S183-S200.

PMID: 35661021 PMC: 9535573. DOI: 10.3233/JPD-223277.

Biomarker of Neuroinflammation in Parkinson's Disease.

Liu T, Chen C, Chang K Int J Mol Sci. 2022; 23(8).

PMID: 35456966 PMC: 9028544. DOI: 10.3390/ijms23084148.

The Use of Antibody Arrays in the Discovery of New Plasma Biomarkers for Endometriosis.

O D, Waelkens E, Vanhie A, Peterse D, Fassbender A, DHooghe T Reprod Sci. 2020; 27(2):751-762.

PMID: 32016799 DOI: 10.1007/s43032-019-00081-w.

References

Olson L, Humpel C . Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer's disease and mild cognitive impairment. Exp Gerontol. 2009; 45(1):41-6. DOI: 10.1016/j.exger.2009.10.011. View

Whitton P . Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol. 2007; 150(8):963-76. PMC: 2013918. DOI: 10.1038/sj.bjp.0707167. View

Heldin C, Westermark B . Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999; 79(4):1283-316. DOI: 10.1152/physrev.1999.79.4.1283. View

Williams D, Lees A . Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol. 2009; 8(3):270-9. DOI: 10.1016/S1474-4422(09)70042-0. View

Nikkhah G, Odin P, Smits A, Tingstrom A, Othberg A, Brundin P . Platelet-derived growth factor promotes survival of rat and human mesencephalic dopaminergic neurons in culture. Exp Brain Res. 1993; 92(3):516-23. DOI: 10.1007/BF00229041. View

Marksteiner J, Kemmler G, Weiss E, Knaus G, Ullrich C, Mechtcheriakov S . Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2009; 32(3):539-40. PMC: 4311051. DOI: 10.1016/j.neurobiolaging.2009.03.011. View

Ben-Jonathan N, Hnasko R . Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001; 22(6):724-63. DOI: 10.1210/edrv.22.6.0451. View

Chen-Plotkin A, Hu W, Siderowf A, Weintraub D, Gross R, Hurtig H . Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol. 2011; 69(4):655-63. PMC: 3155276. DOI: 10.1002/ana.22271. View

Ling H, OSullivan S, Holton J, Revesz T, Massey L, Williams D . Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain. 2010; 133(Pt 7):2045-57. DOI: 10.1093/brain/awq123. View

10.

Scalzo P, Kummer A, Cardoso F, Teixeira A . Increased serum levels of soluble tumor necrosis factor-alpha receptor-1 in patients with Parkinson's disease. J Neuroimmunol. 2009; 216(1-2):122-5. DOI: 10.1016/j.jneuroim.2009.08.001. View

11.

Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K . Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007; 13(11):1359-62. DOI: 10.1038/nm1653. View

12.

Agnoli A, Baldassarre M, Ruggieri S, Falaschi P, Urso R, Rocco A . Prolactin response as an index of dopaminergic receptor function in Parkinson's disease. Correlation with clinical findings and therapeutic response. J Neural Transm. 1981; 51(1-2):123-34. DOI: 10.1007/BF01664010. View

13.

Martignoni E, Horowski R, Liuzzi A, Costa A, Dallabonzana D, Cozzi R . Effects of terguride on anterior pituitary function in parkinsonian patients treated with L-dopa: a double-blind study versus placebo. Clin Neuropharmacol. 1996; 19(1):72-80. DOI: 10.1097/00002826-199619010-00006. View

14.

Scalzo P, Kummer A, Cardoso F, Teixeira A . Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance. Neurosci Lett. 2009; 468(1):56-8. DOI: 10.1016/j.neulet.2009.10.062. View

15.

Abboud S . A bone marrow stromal cell line is a source and target for platelet-derived growth factor. Blood. 1993; 81(10):2547-53. View

16.

Graeber M . Biomarkers for Parkinson's disease. Exp Neurol. 2009; 216(2):249-53. DOI: 10.1016/j.expneurol.2008.12.017. View

17.

Tokuda T, Qureshi M, Ardah M, Varghese S, Shehab S, Kasai T . Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology. 2010; 75(20):1766-72. DOI: 10.1212/WNL.0b013e3181fd613b. View

18.

Mollenhauer B, Locascio J, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher M . α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011; 10(3):230-40. DOI: 10.1016/S1474-4422(11)70014-X. View

19.

Eller M, Williams D . Biological fluid biomarkers in neurodegenerative parkinsonism. Nat Rev Neurol. 2009; 5(10):561-70. DOI: 10.1038/nrneurol.2009.135. View

20.

Hong Z, Shi M, Chung K, Quinn J, Peskind E, Galasko D . DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain. 2010; 133(Pt 3):713-26. PMC: 2842513. DOI: 10.1093/brain/awq008. View